First human tests begin for potential ulcerative colitis drug
NCT ID NCT07350577
Summary
This is a very early, first-in-human study to check the basic safety of a new drug called ALTB-268, which is being developed for ulcerative colitis. It will be given as a single intravenous dose to 24 healthy volunteers to see how their bodies react to it and process it. The main goal is to find a safe dose and understand the drug's side effects before testing it in people who have the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Syneos Health Clinical Research Services, LLC
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.